Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Solid Tumors 5Unspecified Adult Solid Tumor, Protocol Specific 2Refractory Solid Tumors 2Solid Tumors Refractory to Standard Therapy 1Solid Tumor 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Malignant Solid Tumour 1Central Nervous System Metastases 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

Sorafenib 3pazopanib 2Sunitinib 2verubulin 1trifluridine tipiracil drug combination 1irinotecan sucrosofate 1eribulin 1Valproic Acid 1Temozolomide 1Sirolimus 1Irinotecan 1Interleukin-27 1Hydralazine 1Erlotinib Hydrochloride 1Azurin 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Refractory Solid Tumors × Sunitinib × Other solid neoplasm × Clear all
NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT02691793 2022-06-15

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase 4 Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡